Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 431

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment

Edwards, Jarem, Wilmott, James S., Madore, Jason, Gide, Tuba Nur, Quek, Camelia, Tasker, Annie, Ferguson, Angela, Chen, Jinbiao, Hewavisenti, Rehana, Hersey, Peter, Gebhardt, Thomas, Weninger, Wolfgang, Britton, Warwick J., Saw, Robyn P.M., Thompson, John F., Menzies, Alexander M., Long, Georgina V., Scolyer, Richard A., Palendira, Umaimainthan·2018·Clinical Cancer Research

Abstract

Purpose: Therapeutic blockade of immune checkpoints has revolutionized cancer treatment. Durable responses, however, occur in less than half of those treated, and efforts to improve treatment efficacy are confounded by a lack of understanding of the characteristics of the cells that initiate antitumor immune response. Patients and Methods: We performed multiparameter flow cytometry and quantitative multiplex immunofluorescence staining on tumor specimens from immunotherapy-naïve melanoma patients and longitudinal biopsy specimen obtained from patients undergoing anti–PD-1 therapy. Results: Increased numbers of CD69+CD103+ tumor-resident CD8+ T cells were associated with improved melanoma-specific survival in immunotherapy-naïve melanoma patients. Local IL15 expression levels strongly correlated with these tumor-resident T-cell numbers. The expression of several immune checkpoints including PD-1 and LAG3 was highly enriched in this subset, and these cells significantly expanded early during anti–PD-1 immunotherapy. Conclusions: Tumor-resident CD8+ T-cell numbers are more prognostic than total CD8+ T cells in metastatic melanoma. In addition, they are likely to initiate response to anti–PD-1 and anti–LAG-3 treatments. We propose that the immune profile of these cells prior to treatment could inform strategies for immune checkpoint blockade. Clin Cancer Res; 24(13); 3036–45. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2257

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 431

Metadata

Authors
Edwards, J., Wilmott, J. S., Madore, J., Gide, T. N., Quek, C., Tasker, A., Ferguson, A., Chen, J., Hewavisenti, R., Hersey, P., Gebhardt, T., Weninger, W., Britton, W. J., Saw, R. P. M., Thompson, J. F., Menzies, A. M., Long, G. V., Scolyer, R. A., & Palendira, U.
Venue
Clinical Cancer Research
Published
2018-07-01
Volume
24
Issue
13
Pages
3036-3045
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2795035720
Cited by
431
References
44
FWCI
13.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2257
The paper
Edwards, J., Wilmott, J. S., Madore, J., Gide, T. N., Quek, C., Tasker, A., Ferguson, A., Chen, J., Hewavisenti, R., Hersey, P., Gebhardt, T., Weninger, W., Britton, W. J., Saw, R. P. M., Thompson, J. F., Menzies, A. M., Long, G. V., Scolyer, R. A., & Palendira, U. (2018). CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.